Aminosalicylic acid delayed-release granules - Jacobus Pharmaceutical/Lucane Pharma

Drug Profile

Aminosalicylic acid delayed-release granules - Jacobus Pharmaceutical/Lucane Pharma

Alternative Names: 4-Aminosalicylic acid - Lucane Pharma SA; Aminosalicylic acid delayed release granules - Jacobus Pharmaceutical/Lucane Pharma; GranuPAS; Para-aminosalicylic acid (PAS) - Lucane Pharma SA; Para-aminosalicylic acid gastro-resistant granules; PAS-GR; Paser; Paser granules - Jacobus Pharmaceutical/Lucane Pharma

Latest Information Update: 26 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jacobus Pharmaceutical
  • Developer Jacobus Pharmaceutical; Lucane Pharma; Medical Need
  • Class Anti-inflammatories; Antituberculars; Salicylates
  • Mechanism of Action Dihydropteroate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Tuberculosis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 24 Feb 2015 Aminosalicylic acid delayed-release granules - Jacobus Pharmaceutical/Lucane Pharma receives Orphan Drug status for Tuberculosis (Combination therapy) in Australia
  • 30 Mar 2012 Preregistration for multidrug resistant Tuberculosis in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top